Drug exposure in register-based research - An expert-opinion based evaluation of methods

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Tanskanen, Antti ^a,b,c   Taipale, Heidi ^a,c   Koponen, Marjaana ^c   Tolppanen, Anna Maija ^c   Hartikainen, Sirpa ^c,d   Ahonen, Riitta ^c   Tiihonen, Jari ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; MIRTAZAPINE; RISPERIDONE; SIMVASTATIN; WARFARIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; DRUG EXPOSURE; DRUG USE; HUMAN; MEASUREMENT ACCURACY; MEASUREMENT ERROR; MEDICAL EXPERT; MEDICAL RESEARCH; PURCHASING; TABLET FORMULATION; TIME; TREATMENT DURATION; DRUG UTILIZATION; EXPERT WITNESS; MEDICATION ERROR; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PROCEDURES; RESEARCH; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

DRUG PRESCRIPTIONS; DRUG UTILIZATION; EXPERT TESTIMONY; HUMANS; MEDICATION ERRORS; PHARMACOEPIDEMIOLOGY; RESEARCH; TIME FACTORS;

EID: 85029289294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0184070     Document Type: Article

References (30)

1. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006; 15(8):565–74. https://doi.org/10.1002/pds.1230 PMID: 16514590
2. Caetano PA, Lam JMC, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther. 2006; 28(9):1411–24. https://doi.org/10.1016/j.clinthera.2006.09.021 PMID: 17062314
3. WHO. DDD / Definition and general considerations. http://www.whocc.no/ddd/definition_and_general_considera/ (accessed 20 November 2015)
4. Støvring H, Pottegård A, Hallas J. Determining prescription durations based on the parametric waiting time distribution. Pharmacoepidemiol Drug Saf 2016; 25: 1451–1459. https://doi.org/10.1002/pds.4114 PMID: 27670969
5. Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study. PLoS One. 2015; 10(10):e0140598. https://doi.org/10.1371/journal.pone.0140598 PMID: 26469978
6. Romppainen T, Rikala M, Aarnio E, Korhonen MJ, Saastamoinen LK, Huupponen R. Measurement of statin exposure in the absence of information on prescribed doses. Eur J Clin Pharmacol. 2014; 70 (10):1275–6. https://doi.org/10.1007/s00228-014-1737-3 PMID: 25146693
7. Nielsen LH, Løkkegaard E, Andreasen AH and Keiding N. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf. 2008; 17(4): 384–8 https://doi.org/10.1002/pds.1549 PMID: 18213736
8. Burden AM, Paterson JM, Gruneir A, Suzanne M, Cadarette SM. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf. 2015; 24:67–74. https://doi.org/10.1002/pds.3718 PMID: 25331490
9. Johnell K, Fastbom J. The association between use of cardiovascular drugs and antidepressants: a nationwide register-based study. Eur J Clin Pharmacol; 64: 1119–24. https://doi.org/10.1007/s00228-008-0541-3 PMID: 18685838
10. Tanskanen A, Taipale H, Koponen M, Tolppanen A-M, Hartikainen S, Ahonen R, et al. From prescription drug purchases to drug use periods - a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015; 15(1):1–13.
11. Meid AD, Heider D, Adler JB, Quinzler R, Brenner H, Günster C, et al. Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. Pharmacoepidemiol Drug Saf 2016; 25: 1434–42. https://doi.org/10.1002/pds.4091 PMID: 27633276
12. Strandberg AY, Hoti FJ, Strandberg TE, Christopher S, Haukka J, Korhonen P. All-cause and cause-specific mortality among users of basal insulins NPH, detemir, and glargine. PLoS One 2016, 11(3): e0151910. https://doi.org/10.1371/journal.pone.0151910 PMID: 27031113
13. Tolppanen A-M, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research - the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study. Clin Epidemiol. 2013; 5:277–85. https://doi.org/10.2147/CLEP.S46622 PMID: 23950660
14. Abdullah-Koolmees H, Gardarsdottir H, Stoker LJ, Vuyk J, Egberts TCG, Heerdink ER. Discontinuation of somatic medication during psychiatric hospitalization. Ann Pharmacother. 2014; 48(11):1415–24. https://doi.org/10.1177/1060028014544897 PMID: 25078262
15. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol. 2006; 59(1):11–7. https://doi.org/10.1016/j.jclinepi.2005.05.005 PMID: 16360556
16. Weitoft GR, Berglund M, Lindström EA, Nilsson M, Salmi P, Rosén M. Mortality, attempted suicide, rehospitalisation and prescription refill for clozapine and other antipsychotics in Sweden - a register-based study. 2014; 23(3):290–8.
17. Gardarsdottir H, Egberts TC, Stolker, Joost J, Heerdink ER. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: Immortal and neglected time bias. Am J Epidemiol. 2009; 170(3):280–5. https://doi.org/10.1093/aje/kwp142 PMID: 19498074
18. Bakken MS, Engeland A, Engesæter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing. 2013; 42(4):514–20. https://doi.org/10.1093/ageing/aft009 PMID: 23438446
19. Sjösten N, Nabi H, Westerlund H, Salo P, Oksanen T, Pentti J, et al. Effect of depression onset on adherence to medication among hypertensive patients: a longitudinal modelling study. J Hypertens. 2013; 31(7):1477–84; https://doi.org/10.1097/HJH.0b013e32836098d1 PMID: 23666419
20. Østergaard K, Hallas J, Bak S, Christensen R dePont, Gaist D. Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data. Eur J Clin Pharmacol. 2012; 68 (12):1631–7. https://doi.org/10.1007/s00228-012-1293-7 PMID: 22576729
21. Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J. Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol. 2013; 48(4):631–8. https://doi.org/10.1007/s00127-012-0586-6 PMID: 23007295
22. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry. 2012. p. 476–83. https://doi.org/10.1001/archgenpsychiatry.2011.1532 PMID: 22566579
23. Østergaard K, Madsen C, Liu M-L, Bak S, Hallas J, Gaist D. Long-term use of antiplatelet drugs by patients with transient ischaemic attack. Eur J Clin Pharmacol. 2014; 70(2):241–8. https://doi.org/10.1007/s00228-013-1609-2 PMID: 24247641
24. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SYT, Kettunen R, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008; 30 (2):2228–40.
25. Helin-Salmivaara A, Lavikainen P, Ruokoniemi P, Korhonen M, Huupponen R. Persistence with statin therapy in diabetic and non-diabetic persons: a nation-wide register study in 1995–2005 in Finland. Diabetes Res Clin Pract. 2009; 84(1):e9–11. https://doi.org/10.1016/j.diabres.2008.12.015 PMID: 19167127
26. Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clin Epidemiol 2016; 8: 363–371. https://doi.org/10.2147/CLEP.S116160 PMID: 27785101
27. Tanskanen A, Taipale H, Koponen M, Tolppanen A-M, Hartikainen S, Ahonen R, et al. From prescriptions to drug use periods - things to notice. BMC Res Notes. 2014; 7(1):796.
28. Taipale H, Koponen M, Tanskanen A, Tolppanen A, Tiihonen J, Hartikainen S, Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. 2014; 34(4):435–40.
29. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245–51. https://doi.org/10.1007/s10654-010-9451-7 PMID: 20358262
30. Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 2010; 63: 422–427. https://doi.org/10.1016/j.jclinepi.2009.07.001 PMID: 19880282